Chemomab Therapeutics presents data on clinical potential of CM-101

Chemomab Therapeutics reported that it presented two scientific posters supporting the clinical rationale for the company’s primary sclerosing cholangitis program at EASL 2024, the Annual Congress of the European Association for the Study of the Liver, which is taking place June 5-8, 2024 in Milan, Italy. The first EASL poster describes an ex vivo-developed translational assay designed to further characterize the anti-fibrotic activity of CM-101 in patients with liver disease. Using a serum-based ex vivo hepatic stellae cell activation assay derived from patients with liver fibrosis due to metabolic dysfunction-associated steatohepatitis, the study showed that sera from these patients directly activates HSCs and that HSC activation levels were significantly reduced in the sera of patients treated with CM-101. These findings support CM-101’s mode of action in liver fibrosis and are expected to help in characterizing its anti-fibrotic drug effects by serving as a translational tool in PSC clinical trials. In a second poster, researchers presented a comprehensive proteomic profiling study of patients with PSC, which was combined with machine learning-based methods to develop a protein signature model that successfully predicted the presence and severity of PSC when combined with proteins correlated with the Enhanced Liver Function biomarker score. The machine learning analysis was also able to identify key proteins associated with PSC progression. Additionally, the model showed that high CCL24 levels were associated with cirrhosis in patients with PSC.